According to WSJ, Shire plc (SHPG) approached by Takeda Pharmaceutical

POTENTIAL DEAL DETAILS

Takeda Pharmaceutical Co. said it was weighing a bid for rival Shire PLC (SHPG), a potential deal that would create a global drug giant worth nearly $90 billion and mark the latest move in an industry brimming with deal activity.

Update(s):

April 12, 2018: Takeda Pharmaceutical  has sounded out its major creditors for loans, two sources with direct knowledge of the matter said, as it moves closer to a bid for London-listed rare disease specialist Shire (SHPG) that could hit $50 billion.

April 19, 2018: Takeda Pharmaceutical has made a bid for Shire (SHPG) that values the London-listed drugmaker at around $61 billion, two sources with direct knowledge of the matter told Reuters.

April 19, 2018: The Board met again and thoroughly considered the Third Proposal with its advisers and unanimously rejected it, concluding that it continues to significantly undervalue the Company and Shire’s growth prospects and pipeline.

April 19, 2018: Allergan (AGN) confirms that it is in the early stages of considering a possible offer for Shire plc (SHPG). No offer has been made.

April 19, 2018: Following the announcement made earlier today in which Allergan plc (AGN) was identified as a potential bidder for Shire plc (SHPG), Allergan (AGN) now confirms that it does not intend to make an offer for Shire (SHPG) pursuant to Rule 2.7 of the Code.

April 20, 2018: Shire (SHPG) notes the announcement made by Takeda and confirms it has received a fourth proposal on 20 April 2018 regarding a possible offer for the Company (the “Fourth Proposal”)

April 24, 2018: Takeda Pharmaceutical Co. is nearing a preliminary agreement to acquire Shire Plc (SHPG) after the Japanese drugmaker sweetened its roughly $60 billion bid for the biotechnology company, according to people with knowledge of the matter.

April 24, 2018: The Board of Shire  (SHPG) announced earlier today that it had received a further revised proposal from Takeda Pharmaceutical Company Limited (“Takeda”) regarding a possible offer for the Company.

April 25, 2018: Rare disease specialist Shire (SHPG)  said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan’s Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company this year.

May 07, 2018: Takeda is nearing an agreement to buy Shire (SHPG), according to Bloomberg, citing people familiar with the matter. A deal could be announced as early as Tuesday.

May 08, 2018: Takeda Pharmaceutical Company Limited and Shire plc (SHPG) today announced that they have reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire.

Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.